Jacobio Pharmaceuticals Group Co., Ltd.

Research Jacobio Pharmaceuticals Group Co., Ltd. (77V) on Bullrun: market cap EUR 374.42M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• Ticker77V
• ExchangeF
• CountryChina
• SectorHealthcare
• IndustryBiotechnology
• CurrencyEUR
• Market capEUR 374.42M
• Financial periodFY2025
• RevenueEUR 53.53M
• Revenue growth-65.6%
• Net income-EUR 145.98M
• Free cash flow-EUR 212.71M
• Gross margin98.9%

Valuation Snapshot

latest market cap is EUR 374.42M.

About Jacobio Pharmaceuticals Group Co., Ltd.

Jacobio Pharmaceuticals Group Co., Ltd., an investment holding company, engages in the in-house discovery and development of oncology therapies in the People's Republic of China. The company develops sitneprotafib (JAB-3312), an oral allosteric SHP2 inhibitor that is in a Phase III trial for non-small cell lung cancer (NSCLC); glecirasib (JAB-21822), a KRAS G12C allosteric inhibitor in Phase II trials for NSCLC, multi-tumor basket, and colorectal cancer;

Frequently asked questions

What is Jacobio Pharmaceuticals Group Co., Ltd.'s market cap?

Jacobio Pharmaceuticals Group Co., Ltd.'s market capitalization is EUR 374.42M.

What does Jacobio Pharmaceuticals Group Co., Ltd. do?

Jacobio Pharmaceuticals Group Co., Ltd., an investment holding company, engages in the in-house discovery and development of oncology therapies in the People's Republic of China.